Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

NCT03742245 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Metastatic
Breast Cancer

Interventions

DRUG: Olaparib
DRUG: Vorinostat

Sponsor

The Methodist Hospital Research Institute

Collaborators

[object Object]
[object Object]